{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T16:50:54Z","timestamp":1781801454875,"version":"3.54.5"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T00:00:00Z","timestamp":1688688000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Reports on Lenvatinib-based therapies show promising treatment outcomes for patients with unresectable hepatocellular carcinoma (uHCC). However, the effect and safety of Lenvatinib-based therapies still need to be further studies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a retrospective, single-center study on the safety and treatment efficacy of Lenvatinib-based combination therapies for uHCC Patients. The primary endpoints were progression-free survival (PFS) and overall survival (OS). The secondary endpoints were progressive disease (PD), stable disease (SD), partial response (PR), and complete response (CR).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 91 patients, there were 16 females and 75 males with uHCC who received systemic therapies based on Lenvatinib in our center. Forty-six patients (50.5%) received Lenvatinib combined with PD-1 antibody treatment. All these patients also received local therapy with the exception of 2 patients. The remaining 36 patinets received Lenvatinib combined with transcatheter arterial chemoembolization (TACE), 1 patient treated Lenvatinib combined with radiotherapy, 8 patients received Lenvatinib alone. At a median treatment time of 8 months, the objective response rate (ORR) of the entire cohort was 58.2% (53 patients), including 7 patients with CR and 46 patients with PR. 21 patients (23.1%) had SD. The disease control rate (DCR) of all patients was 81.3% (74 patients). However, 17 patients (18.7%) developed PD. The 1- and 2-year cumulative OS rates for the entire cohort were 66.8% and 39.3%, while the corresponding PFS rates were 38.0% and 17.1%, respectively. Univariate and multivariate Cox regression analysis revealed multiple tumor sites to be an independent OS risk factor for uHCC patients (HR=2.204, 95% CI=1.104-4.399, <jats:italic>P<\/jats:italic>=0.025). The most frequently reported adverse events in all patients were AST elevation (51.6%), followed by hypertension (33.0%), ALT elevation (26.4%), and decreased appetite (25.3%). After a combination treatment of Lenvatinib-based therapies, 15 patients met the criteria for salvage liver resection and underwent down-staging hepatectomy with a curative intent. The combination of PD-1 treatment was not very effective in improving the prognosis of uHCC patients treated with Lenvatinib combined with TACE.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our study demonstrated that a proportive of patients benefited from Lenvatinib-based combination therapies with manageable safety profiles, allowing these patients to undergo downstaging surgery with curative intent.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1198562","type":"journal-article","created":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T13:23:21Z","timestamp":1688736201000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy and safety of Lenvatinib-based combination therapies for patients with unresectable hepatocellular carcinoma: a single center retrospective study"],"prefix":"10.3389","volume":"14","author":[{"given":"Jian","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen-Guang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi-Fei","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Xian","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang-Ming","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze-Ya","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei-Ge","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan Yee","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Ping","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,7,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01116-x","article-title":"Lenvatinib: a review in hepatocellular carcinoma","volume":"79","author":"Al-Salama","year":"2019","journal-title":"Drugs"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"3993","DOI":"10.1111\/cas.13806","article-title":"Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model","volume":"109","author":"Kimura","year":"2018","journal-title":"Cancer Sci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.4519","article-title":"A phase ib study of lenvatinib (Len) plus pembrolizumab (Pembro) in unresectable hepatocellular carcinoma (Uhcc)","volume":"38","author":"Zhu","year":"2020","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"vi1","DOI":"10.1093\/annonc\/mdw362.02","article-title":"Lenvatinib mesilate (Len) enhanced antitumor activity of a pd-1 blockade agent by potentiating Th1 immune response","volume":"27","author":"Kato","year":"2016","journal-title":"Ann Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29086","article-title":"Aasld guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2007.01712.x","article-title":"Transcatheter arterial chemoembolization (Tace) in hepatocellular carcinoma (Hcc): the role of angiogenesis and invasiveness","volume":"103","author":"Sergio","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-012-0504-2","article-title":"Predictive value of immunogenic cell death biomarkers Hmgb1, srage, and dnase in liver cancer patients receiving transarterial chemoembolization therapy","volume":"33","author":"Kohles","year":"2012","journal-title":"Tumour Biol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.3.1914","article-title":"Unmasking of alpha-Fetoprotein-Specific Cd4(+) T cell responses in hepatocellular carcinoma patients undergoing embolization","volume":"178","author":"Ayaru","year":"2007","journal-title":"J Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v25.i32.4614","article-title":"Locoregional treatments for hepatocellular carcinoma: current evidence and future directions","volume":"25","author":"Inchingolo","year":"2019","journal-title":"World J Gastroenterol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30010-2","article-title":"Hepatocellular carcinoma","volume":"391","author":"Forner","year":"2018","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1159\/000327577","article-title":"Management of hepatocellular carcinoma in Japan: consensus-based clinical practice guidelines proposed by the Japan society of hepatology (Jsh) 2010 updated version","volume":"29","author":"Kudo","year":"2011","journal-title":"Dig Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.21037\/hbsn-20-480","article-title":"2019 Chinese Clinical guidelines for the management of hepatocellular carcinoma: updates and insights","volume":"9","author":"Xie","year":"2020","journal-title":"Hepatobiliary Surg Nutr"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.9151","article-title":"Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the albi grade","volume":"33","author":"Johnson","year":"2015","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2944","article-title":"Nomograms to predict the long-time prognosis in patients with alpha-fetoprotein negative hepatocellular carcinoma following radical resection","volume":"9","author":"Huang","year":"2020","journal-title":"Cancer Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0212513","article-title":"Lenvatinib plus anti-Pd-1 antibody combination treatment activates Cd8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway","volume":"14","author":"Kato","year":"2019","journal-title":"PloS One"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32023","article-title":"Immunomodulatory effects of lenvatinib plus anti-programmed cell death protein 1 in mice and rationale for patient enrichment in hepatocellular carcinoma","volume":"74","author":"Torrens","year":"2021","journal-title":"Hepatology"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13776","article-title":"Immune-checkpoint inhibitors for advanced hepatocellular carcinoma: a synopsis of response rates","volume":"26","author":"Shek","year":"2021","journal-title":"Oncologist"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.751159","article-title":"Lenvatinib plus immune checkpoint inhibitors improve survival in advanced hepatocellular carcinoma: a retrospective study","volume":"11","author":"Huang","year":"2021","journal-title":"Front Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-013-1969-x","article-title":"Surgical resection versus conformal radiotherapy combined with tace for resectable hepatocellular carcinoma with portal vein tumor thrombus: a comparative study","volume":"37","author":"Tang","year":"2013","journal-title":"World J Surg"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.657512","article-title":"Safety and efficacy of transarterial chemoembolization combined with immune checkpoint inhibitors and tyrosine kinase inhibitors for hepatocellular carcinoma","volume":"11","author":"Yang","year":"2021","journal-title":"Front Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2147\/JHC.S332420","article-title":"Lenvatinib combined with anti-Pd-1 antibodies plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a multicenter retrospective study","volume":"8","author":"Wu","year":"2021","journal-title":"J Hepatocell Carcinoma"},{"key":"B23","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/hep.31022","article-title":"Prediction of survival among patients receiving transarterial chemoembolization for hepatocellular carcinoma: a response-based approach","volume":"72","author":"Han","year":"2020","journal-title":"Hepatology"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2009.02695.x","article-title":"A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization","volume":"9","author":"Lewandowski","year":"2009","journal-title":"Am J Transplant"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1159\/000510299","article-title":"Lenvatinib-transarterial chemoembolization sequential therapy as an effective treatment at progression during lenvatinib therapy for advanced hepatocellular carcinoma","volume":"9","author":"Kawamura","year":"2020","journal-title":"Liver Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2020.11758","article-title":"Lenvatinib prolongs the progression-free survival time of patients with intermediate-stage hepatocellular carcinoma refractory to transarterial chemoembolization: a multicenter cohort study using data mining analysis","volume":"20","author":"Shimose","year":"2020","journal-title":"Oncol Lett"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1007\/s00432-021-03767-4","article-title":"Lenvatinib plus tace with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring pd-L1 expression: a retrospective study","volume":"148","author":"Chen","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.00808","article-title":"Phase ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma","volume":"38","author":"Finn","year":"2020","journal-title":"J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110797","article-title":"The safety and efficacy of lenvatinib combined with immune checkpoint inhibitors therapy for advanced hepatocellular carcinoma","volume":"132","author":"Wang","year":"2020","journal-title":"BioMed Pharmacother"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.653437","article-title":"Neoadjuvant programmed cell death 1 (Pd-1) inhibitor treatment in patients with hepatocellular carcinoma before liver transplant: a cohort study and literature review","volume":"12","author":"Qiao","year":"2021","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1198562\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T13:23:23Z","timestamp":1688736203000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1198562\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,7]]},"references-count":30,"alternative-id":["10.3389\/fimmu.2023.1198562"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1198562","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,7]]},"article-number":"1198562"}}